- Home
- BMRA vs BCDA Comparison
BMRA vs BCDA Comparison
Compare BMRA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- BCDA
- Stock Information
- Founded
- BMRA 1971
- BCDA N/A
- Country
- BMRA United States
- BCDA United States
- Employees
- BMRA N/A
- BCDA N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- BCDA Health Care
- Exchange
- BMRA Nasdaq
- BCDA Nasdaq
- Market Cap
- BMRA 7.4M
- BCDA 7.9M
- IPO Year
- BMRA N/A
- BCDA N/A
- Fundamental
- Price
- BMRA $0.33
- BCDA $2.68
- Analyst Decision
- BMRA
- BCDA Strong Buy
- Analyst Count
- BMRA 0
- BCDA 1
- Target Price
- BMRA N/A
- BCDA $25.00
- AVG Volume (30 Days)
- BMRA 68.2K
- BCDA 73.1K
- Earning Date
- BMRA 10-15-2024
- BCDA 11-06-2024
- Dividend Yield
- BMRA N/A
- BCDA N/A
- EPS Growth
- BMRA N/A
- BCDA N/A
- EPS
- BMRA N/A
- BCDA N/A
- Revenue
- BMRA $5,509,000.00
- BCDA $428,000.00
- Revenue This Year
- BMRA N/A
- BCDA $6.92
- Revenue Next Year
- BMRA N/A
- BCDA N/A
- P/E Ratio
- BMRA N/A
- BCDA N/A
- Revenue Growth
- BMRA 1.74
- BCDA 0.71
- 52 Week Low
- BMRA $0.24
- BCDA $1.96
- 52 Week High
- BMRA $2.13
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- BMRA 47.85
- BCDA 49.01
- Support Level
- BMRA $0.28
- BCDA $2.39
- Resistance Level
- BMRA $0.35
- BCDA $2.90
- Average True Range (ATR)
- BMRA 0.04
- BCDA 0.18
- MACD
- BMRA 0.00
- BCDA -0.00
- Stochastic Oscillator
- BMRA 41.67
- BCDA 53.70
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).